RaQualia Pharma Inc. (4579.T)
Tokyo · JPY · Healthcare · Biotechnology
¥624 (+3.14%) as of
Key statistics
- Market cap
- 16.24B
- P/E (TTM)
- 71.31
- Forward P/E
- 23.91
- EPS (TTM)
- 8.75
- Dividend yield
- 0.00%
- 52-week range
- 438.00 – 1,465.00
- Beta
- 0.87
- Revenue (TTM)
- 3.9B
- Profit margin
- 4.13%
- Volume
- 80.40k
About RaQualia Pharma Inc.
RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. The company human products portfolio includes tegoprazan for gastroesophageal reflux disease; and grapiprant for cancer and pain management; RQ-00000008 for the treatment of osteoarthritis autoimmune disorders; RQ-00000010 to treat gastroparesis. It also provides veterinary products, such as capromorelin to treat anorexia in dogs and weight management in cats; grapiprant for osteoarthritis in dogs; RQ-00000008 to treat osteoarthritis and others; RQ-00317076 for pain; and RQ-00000010 for gut motility disorders, gastroparesis, functional dyspepsia, and chronic constipation. In addition, it provides RQ-00433412 for constipation, and cancer-related anorexia/cachexia syndrome; RQ-00000009 to treat alzheimer's; RQ-00466479, RQ-00350215, and RQ-00434739 to treat chronic pain; RQ-00310941 to treat D-IBS, IBD-remission stage symptoms; RQ-00201894 for gastroparesis, functional dyspepsia, and post-operative ileus; tamibarotene to treat higher-risk myelodysplastic syndrome and acute myeloid leukemia; and FIM-001 for cancer. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Nagoya, Japan
- Employees
- 85
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.